Laurie Toich, Assistant Editor

Synaptic loss in the spinal cord could lead to disability in patients with multiple sclerosis.

Top news of the day from across the healthcare landscape.

Copies of the androgen receptor gene could indicate response to standard prostate cancer drugs.

The Centers for Medicare & Medicaid Services seeks to improve accuracy of data reported from direct and indirect remuneration fees.

Guidance updates plan sponsor and PBM pharmacy quality measures in Medicare Part D.

Immune checkpoint inhibitors have revolutioned cancer treatment, but not all patients respond to immunotherapy.

Lawsuit alleges opioid manufacturers engaged in deceptive marketing that fueled opioid epidemic.

Urinary tract infections, chronic high blood pressure, and blood disorders may increase the risk of pregnancy-related strokes.

The action plan aims to reduce the burden of chronic obstructive pulmonary disease on patients and the healthcare system.

Top news of the day from across the healthcare landscape.

Immunotherapies have improved survival in cancer patients.

Flood of new drug approvals have extended survival across cancer types.

While incidences of metastatic breast cancer are increasing, so is survival.

State lawmakers seek to restrict gifts from pharmaceutical manufacturers to providers.

Value-based care model may eventually replace fee-for-service in physician compensation.

Top news of the day from across the healthcare landscape.

Isentress has been used as a component of treatment regimens for patients diagnosed with HIV-1 for almost a decade.

Health plans have a largely positive view of outcomes-based contracts, survey finds.

Isentress HD is a once daily treatment for HIV-1 that helps patients achieve viral suppression.

Cost of once daily version of Isentress will match price for twice daily HIV drug.

Sleep deprivation could increase sensitivity to pain.

Tocilizumab (Actemra) is the first drug approved to treat giant cell arteritis.

Tocilizumab is the first drug approved to treat giant cell arteritis.

Top news of the day from the healthcare landscape.

Four pharmaceutical companies gained approval for atomoxetine (Strattera).

Professional sample bottles of ticagrelor (Brilinta) may also contain a gout treatment.

Ceritinib (Zykadia) approved to treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

Carboplatin plus birinapant effective against high-grade serious ovarian cancer.

Expanded the indication of Zykadia includes patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

Psychiatric medication could increase fall risk among adults aged 65 and over.